FDA with consumer statement about aspirin for primary prevention of heart disease.\u00a0 they comment:<\/p>\n
Use of Aspirin for Primary Prevention of Heart Attack and Stroke<\/strong><\/p>\n [05\/02\/2014] Cardiovascular disease, including heart disease and stroke, affects tens of millions of people in the United States. \u00a0Consumers and patients who do not suffer from cardiovascular disease sometimes consider taking aspirin to reduce the possibility of having a heart attack or stroke.\u00a0 Reducing the possibility of having a first heart attack or stroke is called primary prevention. \u00a0The FDA has reviewed the available data and does not believe the evidence supports the general use of aspirin for primary prevention of a heart attack or stroke. \u00a0In fact, there are serious risks associated with the use of aspirin, including increased risk of bleeding in the stomach and brain, in situations where the benefit of aspirin for primary prevention has not been established.<\/p>\n The available evidence supports the use of aspirin for preventing another heart attack or stroke in patients who have cardiovascular disease or who have already had a heart attack or stroke. Reducing the risk of additional heart attacks or strokes is known as secondary prevention.\u00a0In patients who have had a cardiovascular event, the known benefits of aspirin for secondary prevention outweigh the risk of bleeding.<\/p>\n FDA is committed to reviewing any data supporting new medicines and new uses to improve the health of the American public.<\/p>\n